{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:17:07Z","timestamp":1782775027045,"version":"3.54.5"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>The use of gonadotropin-releasing hormone analogs (GnRHas) for fertility preservation is not unequivocally accepted. It is controversial whether GnRHa can increase the pregnancy rate in survivors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>This is a retrospective cohort study. Every patient referred for fertility preservation was offered cryopreservation of embryos, ova, and ovarian tissue and GnRHa. The patients were consecutively included. The primary outcome was spontaneous pregnancies. The secondary outcome was cyclic ovarian function (COF) versus premature ovarian failure (POF). These outcomes were assessed 2 years or more after chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>We compared 286 patients who received gonadotropin-releasing hormone agonist (GnRHa) with chemotherapy with 188 patients who were treated with chemotherapy alone. Ovarian function could be determined in 217 patients. Overall, 87% (127 of 146) of the patients in the GnRHa group retained COF and 13% (19 of 146) suffered POF, whereas in the control group, 49% (35 of 71) experienced COF and 51% (36 of 71) suffered POF (p = .0001). The odds ratio (OR) for preserving COF was 6.87 for the patients who received GnRHa (95% confidence interval [CI] 3.4\u201313.4). Overall 60% (112 of 188) of the survivors conceived: 69.3% (84 of 122) of the patients in the GnRHa group compared with 42.4% (28 of 66) in the control group (p = .006). In the GnRHa group, 123 healthy newborns were delivered, versus 40 in the controls. Spontaneous pregnancies occurred in 65.6% (80 of 122) of the survivors in the GnRHa group versus 37.9% (25 of 66) in the control group (p = .0004, OR 3.12, 95% CI 1.7\u20135.8).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Adding GnRHa to chemotherapy significantly increases the OR for spontaneous conception, in addition to COF. It is suggested that GnRHa cotreatment should be added before and during gonadotoxic chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice:<\/jats:title>\n                  <jats:p>The use of gonadotropin-releasing hormone analogs (GnRHa) for fertility preservation is not unequivocally accepted and is even controversial. This study compared 286 patients who received GnRHa with chemotherapy with 188 patients who were treated with chemotherapy alone. Ovarian function could be determined in 217 patients. The odds ratio for preserving cyclic ovarian function was 6.87 for the patients who received GnRHa. Furthermore, the total and spontaneous pregnancy rate was significantly higher for those who received the agonist (p = .006). Adding GnRHa to chemotherapy significantly increased the odds ratio for spontaneous conception, in addition to preserving regular ovarian function. It is suggested that GnRHa cotreatment should be administered to young women in conjunction with gonadotoxic chemotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0223","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T02:09:05Z","timestamp":1444788545000},"page":"1283-1289","source":"Crossref","is-referenced-by-count":59,"title":["Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors"],"prefix":"10.1093","volume":"20","author":[{"given":"Zeev","family":"Blumenfeld","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel"},{"name":"Department of Reproductive Endocrinology, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilli","family":"Zur","sequence":"additional","affiliation":[{"name":"Department of Reproductive Endocrinology, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldad J.","family":"Dann","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,10,13]]},"reference":[{"key":"2021122309360816400_B1","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/annonc\/mdu036","article-title":"\u2018An ounce of prevention is worth a pound of cure\u2019: The case for and against GnRH-agonist for fertility preservation","volume":"25","author":"Blumenfeld","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309360816400_B2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0140-6736(14)60834-5","article-title":"Fertility preservation in women with cancer","volume":"384","author":"De Vos","year":"2014","journal-title":"Lancet"},{"key":"2021122309360816400_B3","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1634\/theoncologist.12-9-1044","article-title":"How to preserve fertility in young women exposed to chemotherapy?: The role of GnRH agonist in addition to cryopreservation of embryos, oocytes, or ovaries","volume":"12","author":"Blumenfeld","year":"2007","journal-title":"The Oncologist"},{"key":"2021122309360816400_B4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/humupd\/dmn022","article-title":"GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy","volume":"14","author":"Blumenfeld","year":"2008","journal-title":"Hum Reprod Update"},{"key":"2021122309360816400_B5","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2013.49.2678","article-title":"Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Loren","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309360816400_B6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.fertnstert.2013.08.012","article-title":"Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: A committee opinion","volume":"100","author":"Practice Committee of American Society for Reproductive Medicine","year":"2013","journal-title":"Fertil Steril"},{"issue":"suppl 6","key":"2021122309360816400_B7","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309360816400_B8","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.fertnstert.2012.07.1144","article-title":"Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation","volume":"98","author":"Blumenfeld","year":"2012","journal-title":"Fertil Steril"},{"key":"2021122309360816400_B9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.fertnstert.2007.02.010","article-title":"Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma","volume":"89","author":"Blumenfeld","year":"2008","journal-title":"Fertil Steril"},{"key":"2021122309360816400_B10","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/annonc\/mdt196","article-title":"Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: The benefit remains uncertain","volume":"24","author":"Turner","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309360816400_B11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ctrv.2013.12.001","article-title":"Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials","volume":"40","author":"Del Mastro","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"2021122309360816400_B12","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/annonc\/mdr575","article-title":"Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial","volume":"23","author":"Behringer","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122309360816400_B13","first-page":"CD008018","article-title":"Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women","volume-title":"Cochrane Database Syst Rev","author":"Chen","year":"2011"},{"key":"2021122309360816400_B14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309360816400_B15","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.26_suppl.105","article-title":"Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients","volume-title":"Paper presented at: ASCO Breast Cancer Symposium","author":"Lambertini","year":"2014"},{"key":"2021122309360816400_B16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.2012.42.8185","article-title":"Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial","volume":"31","author":"Demeestere","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309360816400_B17","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.1378\/chest.128.2_suppl.17S","article-title":"Methodological approach: American College of Chest physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery","volume":"128","author":"Fleisher","year":"2005","journal-title":"Chest"},{"key":"2021122309360816400_B18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00404-009-1308-5","article-title":"GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients","volume":"282","author":"Nitzschke","year":"2010","journal-title":"Arch Gynecol Obstet"},{"issue":"suppl 1","key":"2021122309360816400_B19","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1007\/s10545-009-1095-y","article-title":"Four successful pregnancies in a patient with mucopolysaccharidosis type I treated by allogeneic bone marrow transplantation","volume":"32","author":"Rem\u00e9rand","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"2021122309360816400_B20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1634\/theoncologist.2009-0269","article-title":"Repeated spontaneous pregnancies and successful deliveries after repeated autologous stem cell transplantation and GnRH-agonist treatment","volume":"15","author":"Blumenfeld","year":"2010","journal-title":"The Oncologist"},{"key":"2021122309360816400_B21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(01)05482-4","article-title":"Pregnancy outcomes after peripheral blood or bone marrow transplantation: A retrospective survey","volume":"358","author":"Salooja","year":"2001","journal-title":"Lancet"},{"key":"2021122309360816400_B22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/sj.bmt.1705364","article-title":"Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: Report from the Bone Marrow Transplant Survivor Study","volume":"37","author":"Carter","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2021122309360816400_B23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/jnci\/djj243","article-title":"Premature menopause in survivors of childhood cancer: A report from the childhood cancer survivor study","volume":"98","author":"Sklar","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2021122309360816400_B24","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1200\/JCO.2008.21.1839","article-title":"Ovarian failure and reproductive outcomes after childhood cancer treatment: Results from the Childhood Cancer Survivor Study","volume":"27","author":"Green","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309360816400_B25","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.ejca.2007.06.011","article-title":"Pregnancy in women who had cancer in childhood","volume":"43","author":"Edgar","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122309360816400_B26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mds250","article-title":"Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: Menstruation and pregnancy outcomes","volume":"24","author":"Wong","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309360816400_B27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309360816400_B28","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies-improving the management of early breast cancer: St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0223","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0223","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/11\/1283\/41868858\/oncolo_20_11_1283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/11\/1283\/41868858\/oncolo_20_11_1283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T03:08:48Z","timestamp":1640315328000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/11\/1283\/6399690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,10,13]]},"published-print":{"date-parts":[[2015,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0223","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,11,1]]},"published":{"date-parts":[[2015,10,13]]}}}